ACCESS-SMC gathers leaders in the field to discuss health system strengthening in the post SMC era
Thanks to the ACCESS-SMC project, more than 6 million vulnerable children across seven countries in West Africa: Burkina Faso, Chad, Guinea-Conakry, Mali, Niger, Nigeria and The Gambia will benefit from lifesaving seasonal malaria chemoprevention treatment.
During the first year of mass drug distributions, over 3 million children received SMC, a medicine that prevents children under five from contracting malaria during the rainy season when they are most at risk. This year, over double the children will benefit from SMC as we creep towards the goal of reaching the 25 million eligible children living across the Sahel.
To celebrate the successes of this project and discuss the challenges encountered with this intervention both today and tomorrow, Malaria Consortium will host an ACCESS-SMC symposium in London this coming April. This event will be the opportunity to share key lessons learned from the first at scale SMC implementation in 2015 and will encourage broader coordination and planning for the 2016 SMC campaign. Furthermore this event will gather experts in the field to discuss the market sustainability of SMC and the implications of this campaign on health system strengthening in the Sahel.
Stay tuned for more information on this event coming soon!